New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients

Key Findings

💊 First daily oral GLP-1 pill shows promise in obesity trial

• Elecoglipron (a small molecule taken once daily without food restrictions) produced 2.6-10.5% weight loss compared to 0.6% for placebo in 310 participants over 26 weeks
• 40-89% of patients achieved at least 5% weight loss depending on dose, compared to 16% on placebo
• Side effects were typical GLP-1 class (nausea, constipation, diarrhea) but the convenience factor could be game-changing

⚖️ Most people regain weight rapidly after stopping GLP-1 drugs

• Up to 65% of users discontinue GLP-1 medications within a year of starting them
• Two-thirds of lost weight is typically regained within a year of stopping treatment
• Weight regain reflects biological mechanisms that promote returning to previous weight once appetite suppression is removed

🧠 GLP-1 drug's antidepressant effects work through gut bacteria, not brain receptors

• Liraglutide reduced depression in mice even when GLP-1 brain receptors were blocked or missing entirely
• The drug increased Lactobacillus delbrueckii bacteria, which boosted brain chemicals called endocannabinoids
• Transplanting gut bacteria from liraglutide-treated mice into other mice replicated the antidepressant effects

🏥 GLP-1 users had fewer overdoses and hospitalizations in addiction study

• Among 107,217 patients with both opioid and alcohol use disorders, those prescribed GLP-1 drugs had 52% lower risk of overdose (hazard ratio 0.48)
• GLP-1 users also had reduced rates of substance use disorder-related hospitalizations across most patient subgroups
• Effects were most pronounced in patients also receiving standard addiction medications

💪 Experimental drug preserved muscle mass during GLP-1 weight loss

• Apitegromab (which blocks a muscle-wasting protein called myostatin) prevented 1.9 kg of lean muscle loss compared to placebo in 102 people taking tirzepatide
• Both groups lost similar total weight, but the apitegromab group retained 55% more muscle mass
• This addresses a key concern that rapid weight loss from GLP-1 drugs includes too much muscle loss

🔬 Ketone supplements prevented muscle loss from semaglutide in mice

• Mice given semaglutide alone lost muscle mass and strength, but those also receiving ketone esters maintained both
• Ketone supplementation prevented changes in genes related to muscle breakdown and mitochondrial function
• Fat loss was preserved in both groups, suggesting ketones specifically protected muscle tissue